» Articles » PMID: 24598253

PARP3 Affects the Relative Contribution of Homologous Recombination and Nonhomologous End-joining Pathways

Abstract

The repair of toxic double-strand breaks (DSB) is critical for the maintenance of genome integrity. The major mechanisms that cope with DSB are: homologous recombination (HR) and classical or alternative nonhomologous end joining (C-NHEJ versus A-EJ). Because these pathways compete for the repair of DSB, the choice of the appropriate repair pathway is pivotal. Among the mechanisms that influence this choice, deoxyribonucleic acid (DNA) end resection plays a critical role by driving cells to HR, while accurate C-NHEJ is suppressed. Furthermore, end resection promotes error-prone A-EJ. Increasing evidence define Poly(ADP-ribose) polymerase 3 (PARP3, also known as ARTD3) as an important player in cellular response to DSB. In this work, we reveal a specific feature of PARP3 that together with Ku80 limits DNA end resection and thereby helps in making the choice between HR and NHEJ pathways. PARP3 interacts with and PARylates Ku70/Ku80. The depletion of PARP3 impairs the recruitment of YFP-Ku80 to laser-induced DNA damage sites and induces an imbalance between BRCA1 and 53BP1. Both events result in compromised accurate C-NHEJ and a concomitant increase in DNA end resection. Nevertheless, HR is significantly reduced upon PARP3 silencing while the enhanced end resection causes mutagenic deletions during A-EJ. As a result, the absence of PARP3 confers hypersensitivity to anti-tumoral drugs generating DSB.

Citing Articles

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanoma.

Li Y, Liu Y, Ma J, Yang Y, Yue Q, Zhu G Cell Death Discov. 2025; 11(1):35.

PMID: 39885134 PMC: 11782537. DOI: 10.1038/s41420-025-02296-0.


Mono-ADP-ribosylation, a MARylationmultifaced modification of protein, DNA and RNA: characterizations, functions and mechanisms.

Wu H, Lu A, Yuan J, Yu Y, Lv C, Lu J Cell Death Discov. 2024; 10(1):226.

PMID: 38734665 PMC: 11088682. DOI: 10.1038/s41420-024-01994-5.


Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy.

Zhao S, Prior D, Heske C, Vasquez J Cancers (Basel). 2024; 16(9).

PMID: 38730598 PMC: 11083679. DOI: 10.3390/cancers16091648.


ADP-ribosylation from molecular mechanisms to therapeutic implications.

Suskiewicz M, Prokhorova E, Rack J, Ahel I Cell. 2023; 186(21):4475-4495.

PMID: 37832523 PMC: 10789625. DOI: 10.1016/j.cell.2023.08.030.


Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer.

Lavi E, Lin Z, Ratner E iScience. 2023; 26(10):107934.

PMID: 37810216 PMC: 10558711. DOI: 10.1016/j.isci.2023.107934.


References
1.
Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S . Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2013; 111(1):285-90. PMC: 3890818. DOI: 10.1073/pnas.1309085110. View

2.
Barlow J, Lisby M, Rothstein R . Differential regulation of the cellular response to DNA double-strand breaks in G1. Mol Cell. 2008; 30(1):73-85. PMC: 2440653. DOI: 10.1016/j.molcel.2008.01.016. View

3.
Mansour W, Rhein T, Dahm-Daphi J . The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res. 2010; 38(18):6065-77. PMC: 2952854. DOI: 10.1093/nar/gkq387. View

4.
De Vos M, Schreiber V, Dantzer F . The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012; 84(2):137-46. DOI: 10.1016/j.bcp.2012.03.018. View

5.
Costelloe T, Louge R, Tomimatsu N, Mukherjee B, Martini E, Khadaroo B . The yeast Fun30 and human SMARCAD1 chromatin remodellers promote DNA end resection. Nature. 2012; 489(7417):581-4. PMC: 3493121. DOI: 10.1038/nature11353. View